Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)

Introduction: The combination of immune checkpoint inhibitors with chemotherapy is the standard treatment for extensive-stage (ES) SCLC. However, its safety for elderly patients is not fully validated. We evaluated the safety and efficacy of durvalumab plus carboplatin and etoposide in elderly patie...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Hidenobu Ishii, MD, PhD, Koichi Azuma, MD, PhD, Yuta Yamanaka, MD, Hiroshige Yoshioka, MD, PhD, Yukihiro Toi, MD, Naoki Shingu, MD, Katsuhiko Naoki, MD, PhD, Masaki Okamoto, MD, PhD, Yuko Tsuchiya-Kawano, MD, PhD, Taishi Harada, MD, Hiroyuki Inoue, MD, PhD, Hiroshi Ishii, MD, PhD, Kazunori Tobino, MD, PhD, Chiho Nakashima, MD, PhD, Yoshifusa Koreeda, MD, Yasushi Hisamatsu, MD, Shinsuke Tsumura, MD, Takashi Inagaki, MD, Keiko Mizuno, MD, PhD, Takayuki Shimose, MMath, Isamu Okamoto, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Subjects:	Small cell lung cancer Durvalumab Elderly Immunotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364325000529